Immunogenicity of biologic therapies for migraine: a review of current evidence

Immunogenicity of biologic therapies for migraine: a review of current evidence

Abstract Background Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical trials along with favorable safety and tolerabili...

Full description

Bibliographic Details
Main Authors: Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, Michele Rasamoelisolo, Verena Ramirez Campos, Michael J. Seminerio, Lynda J. Krasenbaum, Honglue Shen, Jennifer Stratton
Format: Article
Language:English
Published: BMC 2021-01-01
Series:The Journal of Headache and Pain
Subjects:
Migraine prevention
Prophylaxis
CGRP pathway–targeted monoclonal antibodies
Immunogenicity
Anti-drug antibodies
Online Access:https://doi.org/10.1186/s10194-020-01211-5

Similar Items

Similar Items